Vmbook Online ordering

Generex Biotechnology Corp

Generex Biotechnology Corp. is a public company that is traded on the Over-the-Counter (OTC) market in the USA, under the ticker symbol GNBT. The company is a biotechnology company that is focused on the development and commercialization of diagnostic and therapeutic products for cancer and diabetes.

Generex's main platform is its proprietary liquid biopsy technology, which is used to detect cancer at an early stage through the detection of circulating tumor cells (CTCs) in the blood. The company's liquid biopsy technology is marketed under the Iris platform and is being developed for use in a variety of clinical applications, including the early detection of cancer, monitoring of treatment response, and the identification of residual disease.

In addition to its liquid biopsy technology, Generex is also developing a number of other product candidates for the treatment of cancer and diabetes. These include immunotherapeutic approaches, such as the use of dendritic cells to stimulate an immune response against cancer, and small molecule drugs for the treatment of diabetes.

Generex was founded in 1997 and is headquartered in Miramar, Florida. As a public company, Generex files regular financial reports with the Securities and Exchange Commission (SEC), which can be accessed on the SEC's website or through the company's website. It is always recommended to do thorough research and possibly consult a financial advisor before making any investment decisions.